Long Acting Edge Delpor’s technology enables sustained drug release for a year or longer after a single administration, addressing adherence issues and the challenge of short half-life drugs. This makes it well suited for CNS and psychiatric conditions, chronic pain, and autoimmune diseases where adherence is critical. Positive phase two data for DLP-114 demonstrate safety and efficacy, strengthening the value proposition for partners seeking durable dosing solutions.

Strategic Licensing Partnerships As a clinical-stage company with validated external interest from physicians and payers, Delpor can pursue licensing or co-development deals to scale faster. The combination of proven science, favorable market feedback, and a track record of external funding support supports compelling terms for large pharma seeking differentiation through long-acting delivery. Target partnerships that leverage Delpor's platform to co-develop or in-license products with unmet adherence needs.

Payer Access Value Positive feedback from payers and high-prescribing physicians positions Delpor to build payer-focused value propositions around adherence benefits and potential cost offsets from reduced relapses or hospitalizations. Early payer engagement and a plan for real-world evidence can accelerate market access and reimbursement discussions. This can inform conversation with risk-sharing models or performance-based milestones in deals.

Global Market Potential Delpor is pursuing multiple therapeutic areas and expresses interest in US and EU markets, creating opportunities for international partnerships and cross-border development. The platform could unlock scale with large global pharma partners that have CNS, autoimmune, or pain portfolios. Early discussions around regulatory pathways and manufacturing readiness can position the company for faster global adoption.

CRO Collaboration Readiness With a lean team, Delpor can accelerate development through CROs and contract manufacturing partners, enabling sponsored research or joint development agreements. Leveraging external clinical and manufacturing capabilities can shorten timelines and reduce capital needs while enabling rapid progression of pipeline products. This approach supports scalable commercialization once a partner is aligned.